论文部分内容阅读
目的探讨突变型p53和CD44v6基因表达产物与肾肿瘤临床行为的关系。方法对98例肾肿瘤石蜡包埋标本,采用免疫组化SP法分别测定突变型p53和CD44v6基因产物,并对肾癌患者5年生存率随访。结果突变型p53与肾癌分期、分级无关,在统计学上均无显著性差异(P>0.05),与5年生存率具有相关性(P<0.05),突变型p53在肾错构瘤组织中呈阴性表达。CD44v6与肾癌分期、分级及5年生存率相关,在统计学上具有显著性差异(P<0.05),CD44v6在错构瘤组织中呈阴性表达。结论突变型p53基因与肾癌发病机制及预后有关,与肾癌恶性程度无关。CD44v6在肾癌发病浸润生长及预后中发挥作用。突变型p53和CD44v6联合检测可能成为评价肾肿瘤临床行为的指标。
Objective To investigate the relationship between the expression of mutant p53 and CD44v6 genes and the clinical behavior of renal tumors. Methods 98 cases of renal tumor paraffin-embedded specimens were detected by immunohistochemical SP method mutated p53 and CD44v6 gene products, and 5-year survival rate of patients with renal cell carcinoma were followed up. Results Mutant p53 had no correlation with the stage and grade of renal cell carcinoma (P> 0.05), but had no correlation with the 5-year survival rate (P <0.05) In negative expression. CD44v6 was correlated with stage, grade and 5-year survival rate of renal cell carcinoma (P <0.05). CD44v6 was negatively expressed in hamartoma. Conclusion Mutant p53 gene is associated with the pathogenesis and prognosis of renal cell carcinoma, but not with the malignant degree of renal cell carcinoma. CD44v6 plays an important role in the growth and prognosis of renal cell carcinoma. Combined detection of mutant p53 and CD44v6 may be an indicator of clinical behavior in renal tumors.